Interleukin-6 - 174G→C Polymorphism Is Associated with Improved Outcome in High-Risk Breast Cancer

Cancer Research

Volumn 63, Issue 22, 2003, Pages 8051-8056

  DeMichele, Angela ^a,b,d   Martin, Anne Marie ^a,b,c   Mick, Rosemarie ^a   Gor, Priya ^a   Wray, Lisa ^b   Klein Cabral, Melissa ^b   Athanasiadis, Galene ^b   Colligan, Theresa ^b   Stadtmauer, Edward ^a,b   Weber, Barbara ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PENNSYLVANIA HOSPITAL   (United States)

^d 14 Penn Tower   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTOSINE; DNA; ESTROGEN RECEPTOR; GUANINE; INTERLEUKIN 6; NUCLEOTIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; AUTOIMMUNE DISEASE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MEGADOSE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOSITY; HOST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MAJOR CLINICAL STUDY; MICROSCOPY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SERUM; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL; TRANSCRIPTION REGULATION;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 10744232313     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Zhang, G. J., and Adachi, I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res., 19: 1427-1432, 1999.
2. Yokoe, T., Iino, Y., and Morishita, Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer, 7: 187-190, 2000.
3. Conze, D., Weiss, L., Regen, P. S., Bhushan, A., Weaver, D., Johnson, P., and Rincon, M. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res., 61: 8851-8858, 2001.
4. Nishimura, R., Nagao, K., Miyayama, H., Matsuda, M., Baba, K., Matsuoka, Y., Yamashita, H., Fukuda, M., Mizumoto, T., and Hamamoto, R. An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer. Oncology, 59: 166-173, 2000.
5. Humphries, S. E., Luong, L. A., Ogg, M. S., Hawe, E., and Miller, G. J. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur. Heart J., 22: 2243-2252, 2001.
6. Cavet, J., Dickinson, A. M., Norden, J., Taylor, P. R., Jackson, G. H., and Middleton, P. G. Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood, 98: 1594-1600, 2001.
7. Hulkkonen, J., Pertovaara, M., Antonen, J., Pasternack, A., and Hurme, M. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology, 40: 656-661, 2001.
8. Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V., Yudkin, J. S., Humphries, S., and Woo, P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Investig., 102: 1369-1376, 1998.
9. Cox, D. R. Regression models and life tables. J. Royal Stat. Soc., 34: 187-220, 1972.
10. Moore, H. C., Mick, R., Solin, L. J., Sickles, C., Mangan, P. A., Luger, S. M., Fox, K. R., Schuchter, L. M., Loh, E., Porter, D. L., Schuster, S., Buzby, G. P., Glatstein, E., Silberstein, L. E., and Stadtmauer, E. A. Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy. Ann. Oncol., 10: 929-936, 1999.
11. Bonafe, M., Olivieri, F., Cavallone, L., Giovagnetti, S., Mayegiani, F., Cardelli, M., Pieri, C., Marra, M., Antonicelli, R., Lisa, R., Rizzo, M. R., Paolisso, G., Monti, D., and Franceschi, C. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur. J. Immunol., 31: 2357-2361, 2001.
12. Nieters, A., Brems, S., and Becker, N. Cross-sectional study on cytokine polymorphisms, cytokine production after T-cell stimulation and clinical parameters in a random sample of a German population. Hum. Genet., 108: 241-248, 2001.
13. Schmidt, S., Papassotiropoulos, A., Bagli, M., Harzheim, M., Heun, R., and Klockgether, T. No association of serum levels of interleukin-6 and its soluble receptor components with a genetic variation in the 3′flanking region of the interleukin-6 gene in patients with multiple sclerosis. Neurosci. Lett., 294: 139-142, 2000.
14. Castell, J. V., Gomez-Lechon, M. J., David, M., Andus, T., Geiger, T., Trullenque, R., Fabra, R., and Heinrich, P. C. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett., 242: 237-239, 1989.
15. Belluco, C., Olivieri, F., Bonafe, M., Giovagnetti, S., Mammano, E., Scalerta, R., Ambrosi, A., Franceschi, C., Nitti, D., and Lise, M. -174G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin. Cancer Res., 9: 2173-2176, 2003.
16. Terry, C. F., Loukaci, V., and Green, F. R. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J. Biol. Chem., 275: 18138-18144, 2000.
17. Purohit, A., Newman, S. P., and Reed, M. J. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res., 4: 65-69, 2002.
18. Qiu, Y., Ravi, L., and Kung, H. J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature (Lond.), 393: 83-85, 1998.
19. Deeble, P. D., Murphy, D. J., Parsons, S. J., and Cox, M. E. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol. Cell. Biol., 21: 8471-8482, 2001.
20. Badache, A., and Hynes, N. E. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res., 61: 383-391, 2001.
21. Oh, J. W., Revel, M., and Chebath, J. A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. Cytokine, 8: 401-409, 1996.
22. Brull, D. J., Lesson, C. P., Montgomery, H. E., Mullen, M., deDivitiis, M., Humphries, S. E., and Deanfield, J. E. The effect of the Interleukin-6-174G > C promoter gene polymorphism on endothelial function in healthy volunteers. Eur. J. Clin. Investig., 32: 153-157, 2002.